Art Therapy for Progressive Supranuclear Palsy
Recruiting in Palo Alto (17 mi)
Age: Any Age
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: Vanderbilt University Medical Center
Disqualifiers: Other neurological diagnosis, impaired cognition
No Placebo Group
Trial Summary
What is the purpose of this trial?Our aim is to study the effect of art therapy for people with PSP, with a focus on alleviating the symptoms associated with PSP, enhancing the overall quality of life for patients, and reducing caregiver stress. Overall, through our collaborative efforts on this study, we hope to unlock the benefits of art therapy for this vulnerable patient population, ultimately improving their overall well-being and enhancing their quality of life.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications.
How does art therapy differ from other treatments for progressive supranuclear palsy?
Art therapy is unique because it focuses on creative expression to improve emotional well-being and quality of life, rather than directly targeting the neurological symptoms of progressive supranuclear palsy. This approach is different from traditional treatments that often involve medications or physical therapies aimed at managing symptoms.
12345Eligibility Criteria
This trial is for individuals who have been diagnosed with progressive supranuclear palsy (PSP) and are able to give informed consent. It aims to help those affected by PSP improve their quality of life and reduce caregiver stress.Inclusion Criteria
I have been diagnosed with progressive supranuclear palsy.
I understand the information given to me and can make decisions about my health care.
Exclusion Criteria
My primary neurological condition is not progressive supranuclear palsy.
I am unable to understand and give consent for treatment.
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
2-4 weeks
Treatment
Participants receive art therapy to alleviate symptoms of PSP and improve quality of life
8-10 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
4 weeks
Participant Groups
The study is exploring the effects of art therapy on patients with PSP. The goal is to see if engaging in art can alleviate symptoms, enhance life quality, and ease the burden on caregivers.
1Treatment groups
Experimental Treatment
Group I: Art TherapyExperimental Treatment1 Intervention
psp patients enrolled into study.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Vanderbilt University Medical CenterNashville, TN
Loading ...
Who Is Running the Clinical Trial?
Vanderbilt University Medical CenterLead Sponsor
CurePSPCollaborator
References
Current and future treatments in progressive supranuclear palsy. [2020]Progressive supranuclear palsy (PSP) is an atypical parkinsonian disorder that, in spite of its growing recognition, is still underdiagnosed. For management, prognosis, and research, an accurate and early diagnosis is essential. PSP is a relentlessly progressive neurodegenerative disorder, clinically characterized by parkinsonism with prominent axial involvement and postural instability, bulbar symptoms, supranuclear ophthalmoplegia, and executive dysfunction. Abnormal neuronal and glial four-repeat tau aggregations affecting the basal ganglia and selective brainstem structures result in dysfunction of the five frontosubcortical circuits and brainstem functions. Primary therapeutic approaches are based on neurotransmitter replacement and palliative strategies. This article reviews the experience and challenges with neurotransmitter replacement and palliative strategies through an extensive literature search of studies published between 1965 and 2005. The role of and limited experience with alternative therapies, such as deep brain stimulation and pallidotomy, are also discussed. Advances in the development of biological therapies for PSP and a better understanding of its etiopathogenesis will likely result from epidemiologic studies and developed four-repeat tau-transgenic animal models. The management of patients with this disorder poses a considerable challenge and includes symptomatic and palliative strategies, as well as education and support, to improve the quality of life for patients and their caregivers.
Toward future therapies in progressive supranuclear palsy. [2005]There is a stern therapeutic challenge for progressive supranuclear palsy (PSP) that has not yet been met. The lack of randomized, controlled trials and negative outcomes from the vast majority of studies make it impossible to set therapeutic standards, or to give clear recommendations. We review progress to date in this area and briefly consider future potential therapeutic strategies.
Physostigmine treatment of progressive supranuclear palsy. [2013]Cognitive and extrapyramidal effects of cholinomimetic therapy were evaluated in 8 patients with progressive supranuclear palsy. Each was randomized to a 10-day double-blind crossover trial of physostigmine and placebo. Physostigmine treatment was associated with marginal and inconsistent changes in long-term memory, suggesting that cholinergic therapy alone is insufficient to restore cognitive function. Motor scores remained unchanged.
[Changes in sleep organization in two patients with progressive supranuclear palsy]. [2006]Sleep-EEG of two subjects affected by Progressive Supranuclear Palsy was studied. Morphological, reduced and poorly organized sleep transients (spindles) in stage 2 and decreased REMs during desynchronized sleep were observed. The quantitative sleep analysis showed a poor and fragmented sleep with an increase of stage 1 and stage 3 and a decrease of stage 2 and REM sleep.
[Descriptive study of a serie of patients affected by progressive supranuclear palsy]. [2013]Progressive supranuclear palsy is a neurodegenerative disorder affecting diverse neurologic systems. The actual treatment response is poor in most patients.